Tag Archives: pharmaceutical policy

Early Access vs. Proven Efficacy: FDA’s Accelerated Approval Process

By | October 24, 2022

A recent JAMA article noted that only one-third of new drug approvals through the accelerated approval process by the FDA in the US or the conditional marketing authorization in the EU have shown therapeutic value.  Many of these drugs are high cost, and this begs the question if we are spending our health care dollars appropriately. … Read More »

Patterns of Buprenorphine-Naloxone Treatment for Opioid Use Disorder

By | May 4, 2017

Despite a rapid expansion in the use of buprenorphine-naloxone (bup-nx) as a treatment for opioid use disorder, there is little understanding of the patterns of treatment. In a newly published-ahead-of-print Medical Care article, Brendan Saloner and colleagues from Johns Hopkins used an all-payer claims database to investigate what factors predict the duration of treatment, dosage, and continuity of treatment for… Read More »